Tobii AB (TOBII)
Nasdaq Stockholm · Sweden · prices in SEK · close of 27 Oct 2026
Key indicators
| Last close | SEK 0.667 |
|---|---|
| 52-week range | 0.593 – 3.400 |
| Return, 1 month / 3 months | −37.7% / −60.8% |
| Return, 1 year / 3 years | −58.7% / −90.6% |
| Trend | Below its 200-day average |
| RSI (14) | 21 |
| Volatility (1 year) | 111.9% |
| Worst drawdown (1 year) | -80.2% |
| Average daily value traded | 1.74M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Tobii AB is a Swedish technology company that develops eye-tracking hardware and software. Its products include eye trackers used in behavioural research, assistive devices that let people with disabilities control computers with their eyes, and eye-tracking components built into computers and games. Customers include research institutions, healthcare and assistive-technology providers, and computer and gaming hardware makers. The company is based in Sweden and works with partners internationally.
The shares are listed on the Nasdaq Stockholm in Sweden under the code TOBII, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Tobii AB (TOBII) trades on the Nasdaq Stockholm in Sweden. It last closed at SEK 0.667 on 27 October 2026.
Its price-based Market X-Ray is 18 out of 100 (a weak price profile), ranking 820 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 58.7% and over the last three months it fell 60.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Stockholm
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 6 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -62.2% | ||
| From 52-week high | -79.3% | ||
| Momentum | 10 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -60.8% | ||
| 6-month return | -69.5% | ||
| 12-month return, skipping the last month | -33.6% | ||
| Stability (higher is calmer) | 12 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 111.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -80.2% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.74M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −41.0% |
|---|---|
| 1 month | −37.7% |
| 3 months | −60.8% |
| 6 months | −69.5% |
| 1 year | −58.7% |
| 3 years | −90.6% |
| 5 years | −97.0% |
Signals
| 50-day / 200-day average | 1.162 / 1.763 |
|---|---|
| Golden / death cross (60 days) | Death, 54 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.081 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Stockholm; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.